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ABSTRACT
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious
disease interventions. We examine the use of these methods in low- and middle-income countries, where infectious
diseases constitute a major burden. This review is comprised of two parts: (1) a summary of dynamic transmission
economic evaluations across all disease areas published between 2011 and mid-2014 and (2) an in-depth review of
mosquito-borne disease studies focusing on health economic methods and reporting. Studies were identiﬁed through
a systematic search of the MEDLINE database and supplemented by reference list screening. Fifty-seven studies
were eligible for inclusion in the all-disease review. The most common subject disease was HIV/AIDS, followed
by malaria. A diverse range of modelling methods, outcome metrics and sensitivity analyses were used, indicating
little standardisation. Seventeen studies were included in the mosquito-borne disease review. With notable
exceptions, most studies did not employ economic evaluation methods beyond calculating a cost-effectiveness ratio
or net beneﬁt. Many did not adhere to health care economic evaluations reporting guidelines, particularly with
respect to full model reporting and uncertainty analysis. We present a summary of the state-of-the-art and offer
recommendations for improved implementation and reporting of health economic methods in this crossover
discipline. © 2016 The Authors. Health Economics published by John Wiley & Sons Ltd.
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1. INTRODUCTION
In recent years development health assistance has grown to exceed US$ 30 billion annually, of which 35%
is directed towards three infectious diseases: HIV/AIDS, malaria and tuberculosis (Dieleman et al., 2014).
Nevertheless, for these and other infectious diseases, ﬁnancing is insufﬁcient for all potential interventions.
Good decision-making on how best to spend available resources can make a substantial difference to
population health. Healthcare economic evaluation can identify where to direct resources so that health
gains are maximised by appraising the health return on investment for technologies and services (Briggs
et al., 2006; Drummond et al., 2005). However, economic evaluation of infectious diseases can be complex
because of the additional indirect effects of infectious disease interventions. That is, a treated or prevented
case is a direct outcome in itself but may also reduce disease transmission including mediation by host
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immunity and drug resistance. Commonly used tools of health economic evaluation modellers such as
decision trees or ‘Markov’ models1 seldom capture these transmission effects. Transmission effects are
the focus of the usually separate ﬁeld of infectious disease mathematical modelling, which aims to simulate
disease transmission in a human population based on human behaviour, biology and epidemiology. By
incorporating information on intervention costs and cost of illness, transmission models can be used for
economic evaluation, thus capturing both the direct and indirect effects of an infectious disease interven-
tion in the evaluation. This is particularly important for the evaluation of interventions and policies that
seek to reduce the transmission of disease, such as mass vaccination, in contrast to interventions that
principally seek to improve direct health outcomes without necessarily impacting disease transmission,
such as case management of severe illness. While these joint models can be complex and computationally
intensive, they are becoming more widely used as the computing capacity readily available to researchers
continues to rise.
In 2011, Jit and Brisson published an introduction to methods for modelling infectious diseases for
decision analysis (a broader discipline that encompasses economic evaluation) (Jit and Brisson, 2011),
and the following year a working group report by Pitman et al., offered some ‘best practices’ in
dynamic transmission modelling for pharmacoeconomics (Pitman et al., 2012). In this review, we use
the term dynamic transmission economic evaluation (DT-EE) and deﬁne as a modelling analysis where i)
the force of infection is dependent on the model state in a previous time step and ii) that makes a comparison
of the costs and effects of one or more interventions or events. DT-EE methodology has thus far been
developed primarily by researchers in high income country (HIC) settings. However infectious diseases
are overwhelmingly a problem of low- and middle-income countries (LMICs), where evidence-based
decision-making stands to make a far greater impact on health. In particular, mosquito-borne diseases such
as malaria and dengue are a major burden in LMICs yet almost absent from HICs. In recent years, resources
available for the control and elimination of mosquito-borne diseases, particularly malaria, have increased
considerably. Political commitment to the elimination of malaria is strong, but the practical approach to
achieve this remains unclear.
To the knowledge of the authors, there are no previous literature reviews on the state-of-the-art of DT-EE,
whether in HICs or LMICs. This review aims to examine the literature base of such studies in LMICs and
examines the scope, methods and reporting of such studies from a health economist’s perspective.
2. METHODS
The review is comprised of two parts: ﬁrst, a broad summary of DT-EE studies in all infectious disease areas
published in the peer-reviewed literature and second, a more in-depth review of DT-EE studies of mosquito-
borne disease interventions. The two-part review provides both an understanding of the application of these
methods across varied disease-speciﬁc research ‘silos’ as well as a more detailed review of mosquito-borne
disease studies.
Studies are included in the general review if (1) the paper compares costs and effects of an infectious
disease intervention; (2) the model includes a dynamic force of infection (i.e. incidence, a rate at which
the susceptible population acquire the infection) that depends on the prevalence of infection at a previous
time point; (3) the paper was published between 1 January 2011 and 31 May 2014; and (4) the study
focuses partially or entirely on a population in a LMIC according to World Bank deﬁnitions (World Bank,
2015). The time period for inclusion in the all-disease review is restricted to recent years because of the
time required to screen articles against the inclusion criteria and to focus on the contemporary state-of-
1In health economics, a Markov model typically uses a pre-deﬁned force of infection. Dynamic transmission models may also hold Markov
properties but are not usually referred to as Markov models.
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the-art DT-EE. Studies are included in the review of mosquito-borne diseases if they meet previous criteria
1–3 and evaluate one or more interventions against a mosquito-borne disease. In this part of the review the
publication year restriction is relaxed to include studies published at any time.
2.1. Search strategy
The literature search is outlined in Figure 1. The MEDLINE database was searched for and was applied to the
MEDLINE database. There are four main components to this initial search:
1. Cost OR economic* (wildcard is used to include word extensions), AND;
2. Infectious OR communicable, AND;
3. Dynamic OR transmission, AND;
4. Date: January 2011–May 2014
The terms ‘cost’ and ‘economic*’ were restricted to title or abstract, while other terms were applied to any
ﬁeld. This search strategy aims to be as sensitive as possible while returning a feasible number of abstracts to be
screened. Secondly, the initial search results were supplemented by a series of additional disease-speciﬁc
searches:
1. (Transmission OR dynamic) AND ((compartmental model OR stochastic*) OR individual-based model)
AND
2. Cost [title/abstract] AND effect*
3. Date: January 2011–May 2014
4. Speciﬁc disease, for example, HIV OR AIDS OR HIV/AIDS
Figure 1. Database search and screening of identiﬁed records
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Disease-speciﬁc search terms included HIV/AIDS, malaria, tuberculosis, inﬂuenza, schistosomiasis, polio,
respiratory syncytial virus, hepatitis, human papillomavirus, measles, rabies, cholera, pneumococcal disease,
meningococcal disease, dengue, rabies, yellow fever and ebola.
Further studies were identiﬁed by screening the reference lists of eligible studies or in other relevant reviews
(Gomez et al., 2013; Pérez Velasco et al., 2012; Reiner et al., 2013). Because of the nature of the inclusion
criteria, abstracts were often insufﬁcient to judge eligibility and full-text screening was frequently necessary
to determine eligibility for inclusion. A cross check of the search was performed on a comprehensive database
of health economic evaluations, produced for another paper in this supplement (Pitt et al., 2016). No additional
articles meeting the inclusion criteria were identiﬁed.
The review of mosquito-borne disease DT-EEs includes all those in the all-disease review as well as addi-
tional studies published prior to 2011. Additional studies were identiﬁed through disease-speciﬁc searches
outlined in Figure 1 and screening of reference lists of identiﬁed studies and a recent review of mosquito-borne
disease transmission models (Reiner et al., 2013).
2.2. Data extraction
Both the general and mosquito-borne disease reviews include data extraction on six ﬁelds: disease, interven-
tion, model, outcome measure, sensitivity analysis and journal (Table I). Some studies included more than
one disease, outcome measure or sensitivity analysis therefore totals may exceed 100%. Data extraction for
both the general and mosquito-borne disease reviews was undertaken independently by two reviewers.
Differing results were resolved by discussion until consensus was reached.
Reporting standards have been developed within the ﬁeld of health care economic evaluation so that
readers might appraise the methodological integrity of a study. The most recent and widely accepted are
the Consolidated Healthcare Economic Evaluation Reporting Standards (CHEERS) guidelines (Husereau
et al., 2013). In the mosquito-borne disease review, all studies, including supplementary materials, were
reviewed against the CHEERS guidelines. Data extraction focused on reporting of the basic economic
evaluation framing indicators such as perspective, cost details, model description and sensitivity or
Table I. Data extracted for all-disease review
Field Deﬁnition
1. Disease The infectious disease(s) subject to analysis
2. Intervention The health care technology or programme subject to analysis
3. Model The type of model used. Options include the following:
- Deterministic compartmental
- Stochastic compartmental
- Individual-based model
- Multi-model (two or more of the previously mentioned)
4. Outcome measure The metric used to quantify human health. Options include the following:
- Disability-adjusted life years (DALYs)
- Quality-adjusted life years (QALYs)
- Life years (LYs)
- Infections averted
- Number of deaths or mortality rate
- Net health or monetary beneﬁt (NHB or NMB)
- Fixed endpoint (e.g. elimination)
5. Sensitivity or uncertainty analysis The approach taken to quantify potential variation in
model results. Options include the following:
- Univariate deterministic
- Multivariate or scenario
- Probabilistic
- Structural
6. Journal The name of the publication featuring the study
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uncertainty analyses (points 6, 8, 9, 13b, 15, 16, 17 and 20b). In addition, the use of advanced techniques
was recorded including probabilistic decision analysis (such as cost-effectiveness acceptability curves),
value of information analysis, resource allocation modelling or programme budgeting and marginal analysis
and spatial analysis.
The synthesis of the review examines whether relevant health economic methods are commonly employed
and well reported and makes recommendations for future studies.
3. RESULTS
3.1. Search results
The database searches identiﬁed 2260 published studies for screening (Figure 1). A total of 57 DT-EEs were
identiﬁed for the all-disease review (Agusto and Adekunle, 2014; Alistar et al., 2014a, 2014b; Babigumira
et al., 2011; Bärnighausen et al., 2012; Bishai et al., 2011; Briët et al., 2013; Briet and Chitnis, 2013; Briët
and Penny, 2013; Carrasco et al., 2011; Ciaranello et al., 2011; Cremin et al., 2013; Crowell et al., 2013;
Durham et al., 2013; Dye, 2013; Eaton et al., 2014; Enns et al., 2011; Fitzpatrick et al., 2014; Freiesleben
de Blasio et al., 2014; Giglio et al., 2012; Gomez et al., 2012; Granich et al., 2012; Hontelez et al., 2011,
2013; Hutton and Brandeau, 2013; Kato et al., 2013; Kawai et al., 2012; Keebler et al., 2014; Levin et al.,
2011; Li et al., 2012; Long and Stavert, 2013; Luz et al., 2011; Maire et al., 2011; Mbah et al., 2013a,
2013b; Mbonigaba, 2013; Menzies et al., 2012; Nichols et al., 2013; Okell et al., 2014; Okosun et al.,
2011, 2013; Okosun and Makinde, 2012; Palombi et al., 2012; Prinja et al., 2011; Ross et al., 2011; Sardar
et al., 2013; Sartori et al., 2012; Scott Braithwaite et al., 2014; Stuckey et al., 2014; Terris-Prestholt et al.,
2014; Vanni et al., 2012; Verguet et al., 2013; von Wyl et al., 2012; Wagner and Blower, 2012; Walensky
et al., 2012, 2013; Winetsky et al., 2012).
From this set, 13 studies of mosquito-borne diseases, plus a further 4 studies of mosquito-borne diseases
published prior to 2011, were included in a more detailed review (Briët et al., 2013; Briet and Chitnis, 2013;
Briët and Penny, 2013; Crowell et al., 2013; Durham et al., 2013; Tediosi et al., 2009; Laxminarayan, 2004;
Laxminarayan et al., 2006; Luz et al., 2011; Maire et al., 2011; Okell et al., 2014; Okosun et al., 2011,
2013; Okosun and Makinde, 2012; Ross et al., 2011; Stuckey et al., 2014; Tediosi et al., 2006).
3.2. Summary of recent dynamic transmission economic evaluations in LMICs
By far the most common disease studied in DT-EEs was HIV/AIDS (n = 30, 53%), followed by malaria
(n= 11, 19%). A range of interventions were studied including vaccination (n= 14, 25%) and pharma-
ceutical therapy as either treatment (n = 7, 12%), prophylaxis (n = 5, 9%) or mass administration (includ-
ing mass screening and treatment) (n= 4, 8%). Eighteen studies used a model to consider multiple
interventions simultaneously (32%). As with economic evaluation in other disease areas, pharmaceuti-
cals and other health technologies are better represented than non-technological interventions (Drake
et al., 2012). This review ﬁnds only one study that focuses on a non-technological intervention (Enns
et al., 2011).
The majority of studies (n = 33, 58%) used a deterministic compartmental model, while 18 studies
(32%) used an individual-based model. Three studies (5%) used a stochastic implementation of a compart-
mental model, and a further three studies (5%) deployed multiple model structures. A variety of outcome
metrics were reported, the most common of which were infections averted (n = 40, 69%) and DALYs
(n = 22, 38%). The majority of studies (n = 41, 72%) reported two or more outcome measures. Elimination
was used as an outcome metric by two studies (4%). While not all studies performed explicit sensitivity
analysis, all went some way towards exploring variation in results. The majority of studies conducted
univariate sensitivity analysis (n = 32, 78%), multivariate or scenario analysis (n = 27, 66%) and/or
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probabilistic analysis (n = 19, 46%). Probabilistic analysis was in some cases incorporated into the trans-
mission model from the outset rather than conducted as a post hoc sensitivity or uncertainty analysis.
Results for the all-disease review are summarised in Table II. Studies were published in a wide range of
journals. The most common journal was PLoS One (n = 8, 14%). PLoS Medicine, Vaccine, AIDS and
Malaria Journal had all published four studies each (7%).
Table II. Summary of dynamic transmission economic evaluations in low- and
middle-income contexts (all diseases, 2011 to May 2014)
Field Frequency %
Disease
Cholera 1 2%
Dengue 2 4%
HIV 26 46%
Human papilloma virus 2 4%
Malaria 11 19%
Measles 3 5%
Pandemic inﬂuenza 1 2%
Rabies 1 2%
Seasonal inﬂuenza 1 2%
Tuberculosis 2 4%
Hepatitis A 1 2%
Hepatitis B 1 2%
Herpes simplex virus 1 2%
HIV and tuberculosis 2 4%
HIV and schistosomiasis 2 4%
57 100%
Intervention type
Contact reduction 1 2%
Diagnostic 3 5%
Mass treatment 2 4%
Mass screening and treatment 2 4%
Multiple 18 32%
Prophylaxis 5 9%
Screening 1 2%
Treatment 7 12%
Vaccine 14 25%
Vector control 4 7%
57 100%
Primary outcome
Disability-adjusted life year 22 38%
Elimination 2 3%
Infections averted 40 69%
Life year 12 21%
Mortality 16 28%
Net health beneﬁt 4 7%
Net monetary beneﬁt 4 7%
Quality-adjusted life year 14 24%
114 197%
Model type
Deterministic compartmental 33 58%
Stochastic compartmental 3 5%
Individual 18 32%
Multi-model 3 5%
57 100%
Sensitivity analysis
Univariate 32 78%
Multivariate or scenario 27 66%
Probabilistic 19 46%
Structural 5 12%
83 202%
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3.3. Review of mosquito-borne disease studies
Of the 17 studies of mosquito-borne diseases, 15 consider malaria interventions and two dengue interven-
tions (Table III). A range of interventions were evaluated including vaccination (n=4, 24%), treatment
(n=3, 18%), vector control (n=4, 24%), mass screening (n=1, 6%) and intermittent preventive treatment
(n=1, 6%). Some studies evaluated multiple integrated approaches (n=4, 24%). The evaluation perspective
and time horizon were generally identiﬁable but often not explicitly stated. The same number of studies
purported to take a societal perspective (n=7, 41%) as a provider perspective (n=7, 41%), but it was
not always clear that all relevant societal costs, such as patient ﬁnancial costs and the opportunity costs
of patient and caregivers’ time were included in studies reporting a societal perspective. Time horizons
varied considerably, and most studies did not include time horizon in the sensitivity analysis. The most
common outcome metrics reported were DALYs (n=9) and infections averted (n=9). No studies explicitly
cited elimination as an outcome metric; four studies (24%) use the relatively uncommon net health beneﬁt
metric. Clear and detailed costing information is only reported in full in a minority of studies. Cost
information is in some cases fragmented in different sections of the paper or supporting documents and
is usually not tabulated with the other model parameters.
Half the malaria studies (n=9, 53%) used versions of the same ‘open malaria’ individual-based model. One
other malaria study (6%) used a different individual-based model, while the remaining ﬁve malaria studies and
two dengue studies (12%) used deterministic compartmental models. The majority of studies (n=11, 65%) re-
ferred to previously published work for a full description of the transmission model. In some cases, but not all, a
brief description of the model was provided. Conversely, the three studies (18%) by Okosun and colleagues
focused primarily on reporting the description and behaviour of the model, such as the identiﬁcation of equi-
libria, model boundaries and optimal control points (Okosun et al., 2011, 2013; Okosun and Makinde,
2012). In these studies, less attention was paid to the description of and justiﬁcation of economic or operational
factors. A majority of studies conducted a multivariate or scenario sensitivity analysis (n=10, 59%), and just
under half conducted probabilistic analysis (n=8, 47%). A common theme in the quantiﬁcation of parameter
sensitivity or uncertainty is that studies frequently focus principally on epidemiological parameters. In the ma-
jority of studies (n=10, 59%), cost parameters were not included in the sensitivity or uncertainty analysis or
were treated separately. The most common funder was the Bill and Melinda Gates Foundation (n=7, 41%).
One study (6%) was funded by a commercial bed net manufacturer.
The majority of studies (n=14, 82%) did not use advanced health economic methods. The study by Maire
et al. is a notable exception as it used a complex dynamic transmission model to undertake probabilistic
decision analysis and also performed a value of information analysis (Maire et al., 2011). The two dengue
studies also employed probabilistic decision analysis and presented results in terms of a cost-effectiveness
acceptability curve (Durham et al., 2013; Luz et al., 2011). Okell et al. undertook spatially explicit analysis,
applying their model to country-speciﬁc data in sub-Saharan Africa (Okell et al., 2014). No studies included
resource allocation or programme budgeting in their analysis.
4. DISCUSSION
This review outlines the literature base for dynamic transmission economic evaluation (DT-EE) in LMICs and
appraises reporting practices and health economic methods for a smaller number of studies addressing
mosquito-borne disease.
The ﬁrst section of the review outlines the scope of the literature across all disease areas. The majority of
studies consider either HIV or malaria. Both diseases are the focus of major global efforts to reduce disease
transmission and both are relatively well ﬁnanced. The potential impact of efﬁcient resource allocation is
therefore greater and research funds are more readily available. There were notably fewer studies on other
major infectious disease burdens in LMICs, including tuberculosis, pneumonia and diarrhoeal disease. This
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may be to be because of challenges in modelling disease transmission, particularly for pneumonia and
diarrhoeal disease where multiple aetiologies exist. Tuberculosis, like HIV and malaria, has a dedicated model-
ling consortium to support a range of modelling studies including DT-EEs (Dowdy et al., 2014).
The role of DT-EE is particularly important in the evaluation of vaccinations and in the comparison
of multiple interventions. For single intervention evaluations, vaccination was the most common inter-
vention. This is not surprising given the level of investment in the development and implementation
of vaccination programmes and that key beneﬁts of vaccination programmes include herd immunity2;
a reduction in disease transmission that is best captured using dynamic transmission modelling. The
largest share of studies evaluated multiple interventions and intervention combinations rather than single
interventions. Transmission models are well suited to incorporating diverse modes of action for various
interventions simultaneously. Alternative health economic models such as decision trees are usually de-
veloped for a speciﬁc intervention and although they can be used for comparing multiple interventions,
modifying them to include additional interventions and interactions between interventions can be difﬁcult
and cumbersome.
The second stage of the review appraises health economic methods and reporting for set of mosquito-borne
disease studies using existing guidelines for reporting economic evaluations (Husereau et al., 2013), explores
the handling of parameter uncertainty as well as the use of advanced economic methods and makes recommen-
dations for future DT-EEs.
Comprehensive reporting is key to good quality economic evaluation. In some cases, very few of the
CHEERS checklist points were reported well. While this is understandable in that these studies often orig-
inate in the discipline of mathematical modelling, which does not share these reporting norms, transmission
modelling studies that make comparisons of cost and health impact are de facto economic evaluations. This
review ﬁnds three areas where reporting can be improved: evaluation perspective, costing and model
description.
The perspective of the study should be clearly stated and applied equally to costs and effects. Costing
methods and data sources should be clearly described including the approach to discounting, currency
exchanges and a justiﬁcation of what resources were costed. Several studies reference previously pub-
lished work to describe the transmission model. Full reporting of all model and analytical information
in the main body of a paper may not be feasible if the journal does not support technical appendices.
However, without clear communication of methods to the reader, complex models must be taken on trust;
where possible model description should be reported in full. Overall, adherence to the best practices for
undertaking and reporting economic evaluation would improve quality and communication in DT-EEs.
Publication of these studies is across a wide range of journals with diverse specialisations. If the rate
of publication continues to rise, a dedicated journal may help to improve methodology and reporting
practices.
Analysis and communication of uncertainty is particularly important in LMIC DT-EEs. A potential risk
in layering complex analyses on complex models is that detail and complexity can create a perception of
validity. Moreover, in LMICs, data collection systems face considerable challenges and the resulting data
sets may be far from robust. Thorough sensitivity or uncertainty analysis is therefore essential. While all
studies in this review conducted sensitivity analysis to some degree, in many cases the approach was partial
or treated economic and epidemiological parameters separately. This may lead to misinterpretation if con-
ﬁdence or credible intervals are reported for a cost-effectiveness ratio, but only epidemiological uncertainty
is included. Pitman et al. point out that a comprehensive probabilistic analysis may also be problematic if
parameter values cannot be assumed to be independent, that is, if there are unidentiﬁed joint parameters
(Pitman et al., 2012). However if researchers can address this, then probabilistic analysis is likely to be
2Population health impact arising from mass vaccination is greater than the sum of individual vaccine protection. Unvaccinated individuals
also beneﬁt from immunity of the ‘herd’.
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the best approach to quantifying parameter uncertainty. Indeed, parameter ﬁtting processes more common in
transmission modelling methods offer some options for ﬁtting correlated parameters (Li et al., 2010).
Otherwise, a univariate analysis that includes both economic and epidemiological parameters can highlight
key determinants of model uncertainty, allowing direct comparison of uncertainty or sensitivity for all model pa-
rameters. A comprehensive appraisal of parameter uncertainty can be supplemented but not replaced, by further
scenario or multivariate sensitivity analysis. This can, for example, elucidate operational decisions such as
seasonal timing of vaccination or required vaccine uptake at different assumptions of efﬁcacy.
• All epidemiological and economic parameters are fully described and tabulated.
• All studies report a basic description of the model structure and key assumptions. For journals that
support web appendices, the transmission model should be described in full including model equa-
tions, software platform and all analytical processes involved in parameterisation.
• Economic parameters are included along with epidemiological and other parameters in sensitivity and
uncertainty analyses.
• Where appropriate, studies go beyond simple cost-effectiveness ratio or net beneﬁt calculation and
employ advanced economic evaluation methods.
• If publications in this area continue to rise, a dedicated journal could improve methodology and
reporting standards.
Box 1: Recommendations for dynamic transmission economic evaluations:
Most studies did not employ advanced health economic methods and went no further with economic anal-
ysis than calculating disaggregated costs and effects, a cost-effectiveness ratio or net beneﬁt. Those that did
(Luz et al., 2011; Maire et al., 2011) illustrate some of the advantages of probabilistic decision analysis, includ-
ing cost-effectiveness acceptability curves (CEACs), and value of information analysis. For example, the inclu-
sion of CEACs goes some way towards dealing with the uncertainty related to the fact that cost-effectiveness
thresholds for LMICs are usually not well deﬁned. Studies that rely on a single threshold value undermine ef-
forts made to produce more precise estimates of costs and effects through dynamic transmission modelling, by
introducing considerable unquantiﬁed uncertainty in the cost-effectiveness threshold chosen (Drake, 2014;
Lubell, 2014; Marseille et al., 2015; Revill et al., 2014). The presentation of CEACs helps to illustrate the im-
pact of cost-effectiveness threshold choice.
Value of information analysis can indicate the potential value of further research into a decision problem.
The key piece of information provided by value of information analyses is typically an estimate of the monetary
value of completely reducing uncertainty in the decision problem, known as the expected value of perfect in-
formation (EVPI). If the cost of further research to reduce this uncertainty is greater than this value, then the
research is not warranted, and conversely, if the value of information is much greater than the cost of research,
then further research could be of beneﬁt, depending on the extent to which the uncertainty could be resolved
(Briggs et al., 2006). Maire et al. estimate the EVPI, of a pre-erythrocytic malaria vaccine to be $ 1.9 billion,
suggesting that further research to better inform the decisions could be worth investment. This type of analysis
can be extended to estimate the expected value of perfect parameter information, the value of reducing
uncertainty in a speciﬁc parameter, providing more detailed information on the value of uncertainty relating
to speciﬁc parameter, for example, the potential value of reduced uncertainty in vaccine effectiveness. In
general, the application of advanced economic evaluation methods in more DT-EEs could yield useful results.
The two studies by Laxminaryan et al. are worth noting in that they tackle the critical question of antimicro-
bial resistance (Laxminarayan, 2004; Laxminarayan et al., 2006). Dynamic transmission models are an impor-
tant tool in modelling the spread of antimicrobial resistance, and the incorporation of costs into these models
has the potential to quantify the economic impact in addition to the health impact. This is a critical component
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in the evaluation of diagnostics and other interventions that can mitigate the emergence and spread of
resistance. The capacity to incorporate the impact of interventions on the dynamics of drug resistance is a
further example of the ﬂexibility of dynamic transmission modelling.
This review has several limitations. The set of studies identiﬁed was reviewed with the aim of describing the
scope, methods and reporting practices of DT-EEs from the perspective of a health economist. An evaluation of
transmission modelling methods was beyond the scope of this review. Correctly identifying DT-EEs is a challenge
as there is no speciﬁc or succinct label for this type of study. Studies can originate frommathematical modelling or
economic evaluation disciplines, and each has its own standards and reporting norms. Studies that are a combina-
tion of both transmission modelling and economic evaluation methods often do not signpost this clearly in the ab-
stract, and it was frequently necessary to refer to the full text. Even then, eligibility for inclusion in the review was
not always clear as economic evaluations that do not dynamically model disease transmission also use terms such
as ‘dynamic’ and ‘transmission’ (not incorrectly) to describe aspects of their models. The full all-disease review is
therefore limited in its time period because of the challenges of the search and screening processes. Despite the
challenges in the search, this study identiﬁes two literature sets representing a powerful yet relatively uncommon
combination of methods. To the authors’ knowledge, this the ﬁrst review of this literature base.
DT-EE is an emerging ﬁeld at the intersection of two disciplines and is particularly relevant to LMICs,
where infectious diseases constitute an enormous burden on human health. This review outlines the current
landscape in this ﬁeld and identiﬁes priority areas to improve the implementation of methodology and
reporting.
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